Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
|Articles|February 8, 2022
The Mainstream Patient: February 8
Author(s)Linda Stocum, Associate Editor
This week's edition of the Mainstream Patients features stories about the benefits of castor oil, the controversy of fragranced skin care, and more.
Advertisement
In this week’s edition, Self answers why hair gets greasy and InStyle investigates if fragrances skin care is as bad as its reputation. Martha Stewart discusses inflammation aging the skin and Insider talks the newest blue light skin care attempt. Allure highlights radiofrequency skin treatments and why psoriasis treament plans need a mental health component .
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
3
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
4
EB06 Phase 2 Vitiligo Study Receives FDA IND Clearance
5